About Michael Matin
Form D filings for HDL Therapeutics from 2013 to 2023 list Michael Matin as executive officer.
Michael Matin first appears on SEC filings in 2013.
Experience
This experience comes from SEC filings. The years are when the filings name Michael Matin in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Michael Matin works with at each company, as listed on that company's latest Form D.
HDL Therapeutics, Inc. · Form D, Jul 10, 2023